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6ASD and PDA closure with 
CeraTM and CeraFlexTM devices
We discuss our experience using the new CeraTM and CeraflexTM 
(Lifetech, Nashan, Shenzhen, China) devices in closing PDAs, 
an ASD and PFOs. 
PATIENTS
This is a retrospective review of lesions closed using the CeraTM 
and CeraFlexTM devices. 
Routine indications for defect closure were followed. An 
electrocardiogram (ECG) and echocardiogram were performed 
on all patients prior to the procedure. Pre-procedural echo-
cardiogram concentrated on defect size, associated lesions and 
haemodynamic importance. Informed consent was obtained 
and active infection ruled out. All PDAs were haemodynamically 
important and no “silent” PDAs were closed. Procedures were 
performed under deep conscious sedation or general anes-
thesia. Standard prophylactic antibiotic protocols were used 
(Cephalosporin 50mg/kg at start of procedure and 8 hrly IVI 
for 3 doses). Heparin (50UI/kg/IVI) was administered after 
cannulating the vessels, with added doses at 30min intervals if 
necessary. Haemodynamic data were collected and included a 
full set of venous and arterial oxygen saturations, pulmonary 
and systemic pressures for shunt and resistance calculations.  
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INTRODUCTION
Patent ductus arteriosus (PDA) and atrial septal defects (ASD) 
are two of the most common congenital cardiac lesions 
occurring in 0.5/1 000 and 0.67 - 2.1/1 000 of live births 
respectively, with a higher incidence of PDAs in premature 
babies.(1,2) Historically the only treatment available for these 
lesions was surgery. The first percutaneous closure of a PDA by 
Porstman, et al.(2) in 1967 and ASD closure by King and Mills in 
1976,(3)  led to the development of various new techniques and 
devices over the past four decades.(4-6) The advantages of 
percutaneous closure of these lesions are well described and 
are now the standard of care. 
The CeraflexTM devices come loaded, are attached by a nitinol 
wire (Figure 1a) and need to be flushed before implantation. 
The devices are self-expandable and retrievable. Advanced 
technology is used to cover the nitinol surfaces of the device 
with Titanium Nitride (TiN). This reportedly prevents Nickle 
leaching and ensures accelerated endothelialisation for rapid 
defect closure. The softer material provides for a compliant and 
flexible implant. Polytetrafluoroethylene (PTFE) is sewn into the 
PDA devices to decrease residual shunting. The ASD and 
patent foramen ovale (PFO) devices contain a polyethylene 
terephthalate (PET) membrane to ensure lower delivery sheath 
profiles and to promote defect closure. The device and delivery 
sheath sizes are comparable to other commercially available 
devices. Both the CeraTM and CeraFlexTM devices have CE 
approval. 
Introduction and aim: Percutaneous closure of con-
genital cardiac defects is common practice. The aim 
of the study was to describe our experience in closing 
PDAs, PFOs and an ASD using the new CeraTM and 
CeraFlexTM devices. 
Methods: Twenty patients were included in this retro-
spective review. All patients underwent device closure 
with the Cera TM and CeraFlexTM devices.
Results: All attempts at device closure were successful 
(n=20). Indications included PDA (n=16), ASD (n=1) and 
PFO (n=3). Median age at procedure was: PDA 1y 10mo 
(4mo - 10y 4mo), ASD 27y and PFO 50y 9mo (38y - 70y). 
Median weight at procedure was: PDA 10.5kg (4.9kg - 
70kg), ASD 56kg and PFO 82.5kg (80kg - 113kg). Peri-
procedural complications consisted of embolisation of 
2 PDA devices, which could be repositioned. 
Conclusion: The CeraTM and CeraFlexTM devices are 
effective for closure of PDAs, ASDs and PFOs. 
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with a retention skirt and a stent portion (Figure 1b). The 
release mechanism consists of a safety button that needs to be 
triggered and then the release button can be moved backwards. 
This results in the release of the nitinol wire (Figure 1c). The 
CeraTM device implantation system consists of a detachable 
cable which screws into the device. This device is not pre-
loaded and is released by turning the delivery cable anti-
clockwise.  
RESULTS
Twenty devices were implanted: PDA (n=16), ASD (n=1) 
and PFO (n=3). Clinical and implantation data can be viewed 
in Table 1. In the PDA group the median age was 1y 10mo 
(4mo - 10y 4mo) and median weight was 10.5kg (4.9kg - 70kg). 
Male to female ratio was 1:3 (4 males, 12 females). No significant 
gradients were observed in the left pulmonary artery and aorta 
post implantation. Complete closure was obtained in all 
patients. 
The patient with an ASD was a 27-year-old female weighing 
56kg. The median age and weight for PFO closure was 50y 9mo 
(38y - 70y) and 82.5kg (80kg - 113kg) respectively. Peri-pro- 
cedural trans-esophageal echocardiogram confirmed no inter-
ference or obstruction of intra-cardiac structures. 
Complications
No major complications were observed. Two PDA devices 
embolised to the aorta, one immediately after release and the 
other after 12 hours. These devices could be snared and 
repositioned with no further complications (see discussion). All 
patients were discharged within 24 hours, except the 2 patients 
with device embolisations. 
Follow-up
Follow-up periods ranged from 1mo - 25mo. (mean 13.0 ± 
7.6mo). All patients were asymptomatic with complete defect 
closure. There was no aortic or pulmonary artery obstruction 
that was noted on follow-up in the PDA group. In the ASD/
PFO group, the ECGs were normal, the devices were in a good 
position and there was no valvular regurgitation or pericardial 
effusion.   
DISCUSSION
Percutaneous closure of PDAs, ASDs and PFOs is a well-
established technique that has a low complication rate. Our 
experience shows that the CeraTM and CeraFlexTM devices are 
effective in closing PDAs, ASDs and PFOs. Delivery sheath sizes 
are small and similar to other available devices. The release 
TECHNICAL ASPECTS
Standard procedural techniques were used to close these 
defects. Device sizes and delivery sheath dimensions are similar 
to other available devices. Device selection was done using 
the smallest measured diameter plus 2mm in the case of 
PDA closure and no more than 1 - 2mm larger than the ASD 
diameter using the stop flow balloon sizing method for ASD 
closure. The AcuMarkTM (Lifetech Sientific, Nanshan District, 
Shenzen, China) sizing balloon is available in 18mm and 28mm 
diameters. The balloons have 4 radiopaque bands at 10mm, 
5mm and 2mm intervals and can be used as a distance reference. 
These markers are located proximal to the 40mm balloon. This 
is a soft compliant balloon that uses a 0.035 inch. guide wire. 
The PDA device shape is reminiscent of the ADO I (St Jude 
Medical, Cardiovascular Division, St Paul, MN) device design 
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FIGURE 1:  The delivery mechanism and nitinol loop 
that attaches the device to the delivery cable are 
illustrated.
A: Nitinol loop at end of delivery cable.
B:  PDA device attached to the delivery cable before loading.
C:  The delivery mechanism. The orange button must be triggered 
before the blue button can be moved backwards thereby 
releasing the device.
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is comparable to other available devices whilst the ASD and 
PFO devices are considerably less in our setting. An advantage 
of the CeraFlexTM device is that the device is in its final position 
before release due to the nitinol wire mechanism (Figure 3). 
ASD and PFO closure was successful in the selected patients. 
The devices could be recaptured if the position was unac-
ceptable before release. Care was taken to confirm distance 
from AV valves, SVC, IVC and no impingement of the aorta 
before release. If a deficient aortic rim was of concern, the 
device was slightly oversized to prevent aortic impingement. 
Our experience of the 2 PDA devices that embolised merits 
further discussion. Both of these patients were small (4.8kg and 
6kg) and were closed using the smaller device (0406). In one 
patient the device embolised immediately and in the smaller 
infant the embolisation was noted 12 hours post implantation. 
The mechanism of embolisation may be due to a number of 
factors. Incorrect device selection may play a role. We do, 
however, take care not to cross the PDA before initial 
angiogram to ensure accurate measurements. We also use the 
right anterior oblique (RAO) 30o view to measure the PDA in 
more than one plane. We then select a device as recommended 
by the manufacturer. If concern exists about sizing, we advance 
the delivery sheath through the PDA and repeat the aortogram 
for final measurements and sizing. In both cases the smaller 
device was used. One possible explanation is that the smaller 
device may take longer to conform to its original expanded size 
at body temperature. The authors speculate that the most likely 
cause may be that the nitinol wire loop becomes wedged in the 
mesh of the device at the anchor point. The delivery cable acts 
as a slingshot when one tries to withdraw the wire during 
release (Figure 2). Tension remains on the system with pulling 
in the direction of the pulmonary artery. As a result, the device 
jumps in the direction of the aorta on final release (slingshot 
mechanism) and may dislodge. This may be more likely to 
occur in smaller devices.
Following these 2 incidents, we now protect the aorta by 
placing a pigtail catheter in the ductal ampulla before final 
release. We also pull the sheath back into the IVC to reduce 
the tension on the delivery cable and wait for 5 - 10min before 
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TABLE 1: Clinical data
 Device/size
 Number Age M/F Diagnosis Weight (kg) Cera CeraFlex Sheath
 1 2y 10mo M PDA 12.5   6*8mm  7F
 2 4mo F PDA 4.9   4*6mm  6F
 3 10y 4mo F PDA 70   8*10mm  7F
 4 11mo M PDA 6.4   4*6mm  6F
 5 1y 9mo F PDA 10.5 8*10mm    7F
 6 1y 2mo F PDA 10.5   4*6mm  6F
 7 4y 1mo F PDA 19.3 6*8mm    7F
 8 8y F PDA 16   6*8mm  7F
 9 11mo F PDA 6   8*10mm  7F
 10 3y M PDA 13.5  4*6mm 6F
 11 3y 7mo F PDA 14 4*6mm    6F
 12 2y 10mo M PDA 14 6*8mm    7F
 13 1y 11mo F PDA 13   4*6mm  6F
 14 11mo F PDA 6.1   4*6mm  6F
 15 10y F PDA 20   8*10mm  7F
 16 9mo F PDA 7.2   4*6mm  6F
 17 27y M ASD 56   28mm  12F
 18 70y F PFO 113   25mm  10F
 19 38y M PFO 85  18mm 9F














FIGURE 2:  The slingshot mechanism is illustrated.
A:  Tension on the device is noted with the nitinol wire still attached.
B & C: Traction on the device towards the pulmonary artery is demonstrated.
D:  The device then jumps in the direction of the aorta. Note the pigtail catheter in the ductal ampulla.
10
ASD AND PDA CLOSURE
final release. In both of these patients it was possible to snare 
the device in an antegrade fashion and reposition the same 
device with complete occlusion of the defect and no further 
complications.
Limitations
This is a retrospective review with a small number of patients 
and relatively short follow-up. 
CONCLUSION
The CeraTM and CeraFlexTM devices are an effective alternative 
to commercially available devices. Certain precautionary 
measures are advised in small children where smaller devices 
are used. 
Conflict of interest: none declared.
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FIGURE 3:  Illustrates the PFO device.
A & B: Illustrates the PFO device in its final position after deployment, before nitinol wire release.
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